Eli Lilly and Company plans to expand its manufacturing capacity at its facility in Research Triangle Park, North Carolina. The $450 million project is expected to create 100 jobs.

The expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for incretin products that treat diabetes, according to company officials. Eli Lilly anticipates initial production to begin this year, with preparations for inspections by the FDA ongoing.

"As we move into 2023, Lilly is focused on finding innovative solutions to meet the growing demand for our medicines," said Edgardo Hernandez, executive vice president and president, Lilly Manufacturing Operations. "Expanding our operations at Research Triangle Park will accelerate the rate at which we can produce medicines that patients rely on to address serious health challenges like diabetes. We're on track to achieve the goal we shared in November 2022 of doubling incretin capacity by the end of this year, but this investment is key to ensuring even more patients will have access to medicines they need in the future,” he added.

Since 2014, Lilly has introduced 18 new medicines to make life better for people living with diseases like diabetes and cancer and aims to introduce several potential new medicines in 2023.

"When companies already in North Carolina choose to expand here, it reaffirms our status as the best state to do business," Governor Roy Cooper noted. "Our strong communities and our dedicated, well-trained workforce will help Lilly continue to succeed."